Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CRC006
MIFTS: 60

Carcinoid Syndrome

Categories: Rare diseases, Endocrine diseases, Cancer diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Carcinoid Syndrome

About this section

MalaCards integrated aliases for Carcinoid Syndrome:

Name: Carcinoid Syndrome 53
Carcinoid Tumor 53 29 73
Carcinoid Tumor No Icd-O Subtype 73
Malignant Carcinoid Syndrome 73
Carcinoid Tumor Syndrome 53
Carcinoid Tumors 43

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 33


Sources

Summaries for Carcinoid Syndrome

About this section
NIH Rare Diseases : 53 Carcinoid syndrome refers to a group of symptoms that are associated with carcinoid tumors (rare, slow-growing tumors that occur most frequently in the gastroinestinal tract or lungs). Affected people may experience skin flushing, abdominal pain, diarrhea, difficulty breathing, rapid heart rate, low blood pressure, skin lesions on the face (telangiectasias), and wheezing. In later stages, carcinoid syndrome may damage the heart valves, resulting in symptoms of congestive heart failure. The condition occurs when the carcinoid tumor secretes serotonin or other chemicals into the bloodstream. Only 10% of people with carcinoid tumors develop carcinoid syndrome; most have advanced stage carcinoid tumors that have spread to the liver. Treatment generally involves addressing the underlying carcinoid tumor and medications to alleviate symptoms.

MalaCards based summary : Carcinoid Syndrome, also known as carcinoid tumor, is related to carcinoid tumors, intestinal and multiple endocrine neoplasia. An important gene associated with Carcinoid Syndrome is CHGA (Chromogranin A), and among its related pathways/superpathways are Neuroscience and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Miconazole and Oxaliplatin have been mentioned in the context of this disorder. Affiliated tissues include lung, liver and heart, and related phenotypes are right ventricular failure and palpitations

MedlinePlus : 43 Carcinoid tumors are rare, slow-growing cancers. They usually start in the lining of the digestive tract or in the lungs. They grow slowly and don't produce symptoms in the early stages. As a result, the average age of people diagnosed with digestive or lung carcinoids is about 60. In later stages the tumors sometimes produce hormones that can cause carcinoid syndrome. The syndrome causes flushing of the face and upper chest, diarrhea, and trouble breathing. Surgery is the main treatment for carcinoid tumors. If they haven't spread to other parts of the body, surgery can cure the cancer.

Wikipedia : 76 Carcinoid syndrome is a paraneoplastic syndrome comprising the signs and symptoms that occur secondary... more...

Sources

Related Diseases for Carcinoid Syndrome

About this section

Diseases related to Carcinoid Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 239)
# Related Disease Score Top Affiliating Genes
1 carcinoid tumors, intestinal 31.8 CHGA ENO2 MEN1 SST SYP
2 multiple endocrine neoplasia 30.3 CALCA CHGA MEN1
3 gastrointestinal neuroendocrine tumor 30.3 CHGA SST SYP
4 vipoma 30.3 CHGA NTS SST
5 acromegaly 29.2 GHRH IGF1 MEN1 SST
6 somatostatinoma 29.2 CALCA CHGA ENO2 SST
7 zollinger-ellison syndrome 29.2 CHGA GHRH MEN1 NTS SST
8 serotonin syndrome 28.9 CHGA GHRH HTR3A IFNA2 MEN1 PYY
9 multiple endocrine neoplasia, type i 28.8 CHGA GHRH MEN1 SST SYP
10 neuroendocrine tumor 28.5 CALCA CHGA ENO2 MEN1 NTS SST
11 pheochromocytoma 27.9 CALCA CHGA ENO2 MEN1 NPY SST
12 neurofibromatosis-pheochromocytoma-duodenal carcinoid syndrome 12.0
13 gastrointestinal neuroendocrine benign tumor 11.0 CHGA SST
14 esophageal neuroendocrine tumor 10.9 CHGA SYP
15 gastric neuroendocrine neoplasm 10.9 CHGA SST
16 ovarian large-cell neuroendocrine carcinoma 10.9 CHGA SYP
17 acinar cell cystadenocarcinoma 10.9 CHGA SYP
18 peritoneal serous adenocarcinoma 10.9 CHGA SYP
19 cellular ependymoma 10.9 CHGA SYP
20 malignant glandular tumor of peripheral nerve sheath 10.9 SST SYP
21 primary hepatic neuroendocrine carcinoma 10.9 CHGA SYP
22 wdha syndrome 10.9 CALCA SST
23 chordoid meningioma 10.9 CHGA SYP
24 pituitary carcinoma 10.9 CHGA SST
25 conventional angiosarcoma 10.9 CHGA SYP
26 pancreatic gastrinoma 10.8 MEN1 SST
27 hyperinsulinemic hypoglycemia, familial, 2 10.8 CHGA SST
28 prolactin producing pituitary tumor 10.8 CALCA SST
29 leprosy 2 10.8 CALCA NPY
30 pulmonary sclerosing hemangioma 10.8 CHGA SYP
31 acidophil adenoma 10.8 IGF1 SST
32 pituitary infarct 10.7 IGF1 SST
33 reflex sympathetic dystrophy 10.7 CALCA NPY
34 ampulla of vater neoplasm 10.7 SST SYP
35 pulmonary blastoma 10.7 CHGA SYP
36 adenoma of the pancreas 10.7 CHGA SST SYP
37 pituitary adenoma 1, multiple types 10.7 IGF1 SST
38 lymphocytic colitis 10.7 CHGA PYY
39 binswanger's disease 10.7 CHGA SST SYP
40 epispadias 10.7 CALCA NPY
41 ureter, cancer of 10.7 CHGA SYP
42 pancreatic cystadenocarcinoma 10.6 CALCA CHGA SYP
43 non-functioning pancreatic endocrine tumor 10.6 CHGA SYP
44 gastrinoma 10.6 CHGA MEN1 SST
45 tanycytic ependymoma 10.6 CHGA MEN1 SYP
46 osteoporosis, juvenile 10.6 CALCA IGF1
47 ectopic cushing syndrome 10.6 MEN1 SST SYP
48 phaeochromocytoma 10.6 CHGA NPY SST
49 insulinoma 10.6 CHGA MEN1 SST
50 parathyroid adenoma 10.5 CALCA CHGA MEN1

Graphical network of the top 20 diseases related to Carcinoid Syndrome:



Diseases related to Carcinoid Syndrome
Sources

Symptoms & Phenotypes for Carcinoid Syndrome

About this section

Human phenotypes related to Carcinoid Syndrome:

32 (show all 25)
# Description HPO Frequency HPO Source Accession
1 right ventricular failure 32 occasional (7.5%) HP:0001708
2 palpitations 32 occasional (7.5%) HP:0001962
3 nausea and vomiting 32 occasional (7.5%) HP:0002017
4 asthma 32 occasional (7.5%) HP:0002099
5 episodic abdominal pain 32 frequent (33%) HP:0002574
6 hepatic necrosis 32 very rare (1%) HP:0002605
7 paraganglioma 32 very rare (1%) HP:0002668
8 chronic noninfectious lymphadenopathy 32 occasional (7.5%) HP:0002730
9 elevated hepatic transaminases 32 occasional (7.5%) HP:0002910
10 increased serum serotonin 32 occasional (7.5%) HP:0003144
11 myopathy 32 very rare (1%) HP:0003198
12 protracted diarrhea 32 frequent (33%) HP:0004385
13 tricuspid regurgitation 32 occasional (7.5%) HP:0005180
14 small intestine carcinoid 32 frequent (33%) HP:0006722
15 intestinal carcinoid 32 frequent (33%) HP:0006723
16 facial telangiectasia 32 occasional (7.5%) HP:0007380
17 epiphora 32 occasional (7.5%) HP:0009926
18 bronchospasm 32 occasional (7.5%) HP:0025428
19 erythematous plaque 32 frequent (33%) HP:0025474
20 lack of bowel sounds 32 very rare (1%) HP:0030145
21 heart murmur 32 occasional (7.5%) HP:0030148
22 night sweats 32 frequent (33%) HP:0030166
23 atypical pulmonary carcinoid tumor 32 very rare (1%) HP:0030446
24 abnormal b-type natriuretic peptide level 32 occasional (7.5%) HP:0031138
25 rhinorrhea 32 occasional (7.5%) HP:0031417

MGI Mouse Phenotypes related to Carcinoid Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.9 CHGA VEGFA ENO2 GHRH HTR3A IGF1
2 homeostasis/metabolism MP:0005376 9.65 SST CHGA VEGFA GHRH HTR3A IGF1
3 nervous system MP:0003631 9.36 SYP VEGFA ENO2 GHRH HTR3A IGF1
Sources

Drugs & Therapeutics for Carcinoid Syndrome

About this section

Drugs for Carcinoid Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 219)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 22916-47-8 4189
2
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 5310940 9887054 43805 6857599
3
Everolimus Approved Phase 4,Phase 3,Phase 1,Phase 2 159351-69-6 6442177
4
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 53123-88-9 5284616 6436030 46835353
5
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83150-76-9 383414 6400441
6 lanreotide Approved Phase 4,Phase 3,Phase 2,Early Phase 1 108736-35-2
7
Lactitol Investigational Phase 4,Phase 1,Phase 2 585-86-4 3871
8 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
9 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
10 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
11 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
12 Antifungal Agents Phase 4,Phase 3,Phase 1,Phase 2
13 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Angiopeptin Phase 4,Phase 3,Phase 2,Early Phase 1
16 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Cathartics Phase 4
18 Laxatives Phase 4
19 Cola Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20
Tranexamic Acid Approved Phase 3 1197-18-8 5526
21
Fluorouracil Approved Phase 2, Phase 3,Phase 1 51-21-8 3385
22
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 3 216974-75-3
23
Somatostatin Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 38916-34-6, 51110-01-1 53481605
24
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1 68538-85-2
25
Methylene blue Approved, Investigational Phase 3 61-73-4
26
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
27
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
28
Ondansetron Approved Phase 3 99614-02-5 4595
29
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
30
leucovorin Approved, Nutraceutical Phase 2, Phase 3,Phase 3,Phase 1 58-05-9 143 6006
31
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 1 59-30-3 6037
32 tannic acid Approved, Nutraceutical Phase 3
33 Pancreatic Polypeptide Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 59763-91-6
34 interferons Phase 3,Phase 2,Phase 1
35
protease inhibitors Phase 3,Phase 2
36 3-Iodobenzylguanidine Phase 3,Phase 1
37 Coagulants Phase 3
38 Hemostatics Phase 3
39 HIV Protease Inhibitors Phase 3,Phase 2
40 Hormone Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
41 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 3,Phase 1
42 Hormones Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
43 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 3,Phase 1
44 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
45 Interferon-alpha Phase 3,Phase 2
46 Antifibrinolytic Agents Phase 3
47 Radiopharmaceuticals Phase 3,Phase 1,Phase 2,Not Applicable
48 Antimetabolites Phase 2, Phase 3,Phase 1
49 Antiviral Agents Phase 3,Phase 2
50 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 199)
# Name Status NCT ID Phase Drugs
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
2 Somatuline Autogel Preference and Health Economy Study Completed NCT00681187 Phase 4 lanreotide (Autogel formulation)
3 Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. Recruiting NCT01789281 Phase 4 Everolimus;Sandostatin LAR Depot
4 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
5 The Role of Inhalations of Tranexamic Acid in Patients With Hemoptysis Unknown status NCT01496196 Phase 3 tranexamic acid;tranexamic acid
6 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
7 An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome Completed NCT00774930 Phase 3 Lanreotide;Placebo
8 Telotristat Etiprate for Carcinoid Syndrome Therapy Completed NCT02063659 Phase 3 Telotristat etiprate;Placebo
9 TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) Completed NCT01677910 Phase 3 Telotristat etiprate;Placebo-matching telotristat etiprate
10 Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor Completed NCT00412061 Phase 3 Octreotide;Placebo;Everolimus
11 Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) Completed NCT01626378 Phase 3 TRx0237;Placebo
12 Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease Completed NCT00690430 Phase 3 Pasireotide;Octreotide
13 Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors Completed NCT00442533 Phase 2, Phase 3 Indium-111 pentetreotide
14 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
15 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3 dexamethasone;ondansetron
16 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3
17 Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms Active, not recruiting NCT02026063 Phase 3 Telotristat etiprate tablets (250 mg)
18 A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours Active, not recruiting NCT01578239 Phase 3 Octreotide LAR;177Lu-DOTA0-Tyr3-Octreotate
19 Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor Active, not recruiting NCT00569127 Phase 3 Octreotide Acetate
20 Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery Not yet recruiting NCT03375320 Phase 3 Cabozantinib S-malate
21 Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome Terminated NCT00092287 Phase 3 lanreotide Autogel (somatostatin analogue);Sandostatin long acting release (LAR) Depot (somatostatin analogue)
22 Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion Terminated NCT00227136 Phase 3 5-Hydroxy-Tryptamine
23 Randomized Phase III of PRRT Versus Interferon Withdrawn NCT01860742 Phase 3 Interferon alpha-2b;177Lu-DOTATATE
24 Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer Unknown status NCT00019474 Phase 2 fluorouracil;hydroxyurea
25 Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor Unknown status NCT01175096 Phase 1, Phase 2 RAD001 (everolimus, Afinitor®)
26 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms Unknown status NCT01237457 Phase 2 177Lu-DOTATATE
27 Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors Unknown status NCT02455596 Phase 2 Recombinant anti-tumor and anti-virus protein for injection (Novaferon)
28 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
29 Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Completed NCT01104415 Phase 2 Low Dose LX1606 - Day 1 (start);Mid-low dose LX1606 - Day 15 (start);Mid-high dose LX1606 - Day 29 (start);High dose LX1606 - Day 43 (start)
30 Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy Completed NCT00853047 Phase 2 Low Dose LX1606 Part 1;Mid-Low Dose LX1606 Part 1;Mid-High Dose LX1606 Part 1;High Dose LX1606 Part 1;Part 2 LX1606 Expanded Cohort;Placebo;LX1606 Open Label Dose Extension;LX1606 Open Label Extension 2;LX1606 Open Label Extension 3
31 Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors Completed NCT00088595 Phase 2 Pasireotide (SOM230)
32 Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) Completed NCT02299089 Phase 2 octreotide FluidCrystal® injection depot
33 Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors Completed NCT00002470 Phase 2 fluorouracil
34 Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors Completed NCT00055809 Phase 2
35 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
36 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
37 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
38 Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma Completed NCT00093782 Phase 2 temsirolimus
39 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
40 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
41 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
42 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
43 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
44 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
45 Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction Completed NCT00004911 Phase 1, Phase 2
46 Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction Completed NCT00004910 Phase 1, Phase 2
47 Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer Completed NCT00005049 Phase 2 carboplatin;cisplatin;floxuridine
48 A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors Completed NCT00328497 Phase 2 Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)
49 A Study of Axitinib in Advanced Carcinoid Tumors Completed NCT01435122 Phase 2 Axitinib
50 EPO906 in Carcinoid and Other Neuroendocrine Tumors Completed NCT00050349 Phase 2 EPO906 epothilone B

Search NIH Clinical Center for Carcinoid Syndrome

Inferred drug relations via UMLS 73 / NDF-RT 51 :
Sources

Genetic Tests for Carcinoid Syndrome

About this section

Genetic tests related to Carcinoid Syndrome:

# Genetic test Affiliating Genes
1 Carcinoid Tumor 29
Sources

Anatomical Context for Carcinoid Syndrome

About this section

MalaCards organs/tissues related to Carcinoid Syndrome:

41
Lung, Liver, Heart, Skin, Breast, Small Intestine, Appendix
Sources

Publications for Carcinoid Syndrome

About this section

Articles related to Carcinoid Syndrome:

(show top 50) (show all 971)
# Title Authors Year
1
Cost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogs. ( 28959913 )
2018
2
Developments in the treatment of carcinoid syndrome - impact of telotristat. ( 29503551 )
2018
3
Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. ( 29330194 )
2018
4
LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAA8VE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY. ( 29547049 )
2018
5
Carcinoid-syndrome: recent advances, current status and controversies. ( 29120923 )
2018
6
Telotristat Ethyl for Patients With Carcinoid Syndrome Associated With Chest Pain and Hypertension. ( 29232344 )
2018
7
A case of a primary lung cancer comprised of adenocarcinoma and atypical carcinoid tumor with both components harboring BRAF p.V600E mutation. ( 29248665 )
2018
8
The management of refractory carcinoid syndrome: challenges and opportunities ahead. ( 29039712 )
2018
9
Diagnostic Dilemma: Carcinoid Syndrome. ( 29906424 )
2018
10
Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome. ( 29724499 )
2018
11
Telotristat ethyl: a novel agent for the therapy of carcinoid syndrome diarrhea. ( 29350062 )
2018
12
Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) Syndrome and Carcinoid Tumors With/Without NECH: A Clinicopathologic, Radiologic, and Immunomolecular Comparison Study. ( 29438170 )
2018
13
Telotristat Ethyl: A Review in Carcinoid Syndrome Diarrhoea. ( 29931594 )
2018
14
Outcomes of Surgical and Chemotherapeutic Treatments of Goblet Cell Carcinoid Tumors of the Appendix. ( 29916007 )
2018
15
A Case of Carcinoid Syndrome Due to Malignant Metastatic Carcinoid Tumor with Carcinoid Heart Disease Involving Four Cardiac Valves. ( 29527003 )
2018
16
Advances in the management of patients with carcinoid syndrome. ( 28591101 )
2017
17
Partial nephrectomy in horseshoe kidney: Primary carcinoid tumor. ( 29473385 )
2017
18
Anesthetic Management of Patients With Carcinoid Syndrome and Carcinoid Heart Disease: The Mount Sinai Algorithm. ( 29273478 )
2017
19
Incidence and prognosis of carcinoid syndrome: hormones or tumour burden? ( 28593854 )
2017
20
Demonstrating Hickam's Dictum: Metachronous Pulmonary Adenocarcinoma, Carcinoid Tumor, and Histoplasmosis. ( 28690073 )
2017
21
Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients. ( 28642335 )
2017
22
Predictive factors associated with carcinoid syndrome in patients with gastrointestinal neuroendocrine tumors. ( 29142475 )
2017
23
Carcinoid tumor arising from a retroperitoneal mature cystic teratoma. ( 29295805 )
2017
24
Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea. ( 29051994 )
2017
25
Budgetary Impact of Telotristat Ethyl, a Novel Treatment for Patients with Carcinoid Syndrome Diarrhea: A US Health Plan Perspective. ( 29175096 )
2017
26
Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR. ( 28562131 )
2017
27
Carcinoid syndrome in neuroendocrine tumors: a prognostic effect? ( 28238598 )
2017
28
Metastatic Recurrence of Typical Pulmonary Carcinoid Accompanied by Carcinoid Syndrome, Successfully Treated with Octreotide LAR. ( 29445555 )
2017
29
Carcinoid Syndrome Complicating a Pancreatic Neuroendocrine Tumor: A Case Report. ( 29040196 )
2017
30
Retrospective review of serotonergic medication tolerability in patients with neuroendocrine tumors with biochemically proven carcinoid syndrome. ( 28267211 )
2017
31
Telotristat ethyl (Xermelo) for carcinoid syndrome diarrhea. ( 28699933 )
2017
32
Refractory carcinoid syndrome: a review of treatment options. ( 28203303 )
2017
33
Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. ( 27918724 )
2017
34
Carcinoid Syndrome and Carcinoid Heart Disease as Manifestations of Non-Metastatic Ovarian Neuroendocrine Tumour. ( 28865508 )
2017
35
Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. ( 28444114 )
2017
36
Lymphoid follicular proctitis resembling rectal carcinoid tumor, confirmed by endoscopic resection. ( 28415161 )
2017
37
Incidence and prognosis of carcinoid syndrome: hormones or tumour burden? - Authors' reply. ( 28593855 )
2017
38
Carcinoid Syndrome ( 28846309 )
2017
39
Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. ( 28238592 )
2017
40
Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl. ( 29074312 )
2017
41
Metastatic Mucinous Adenocarcinoma and Carcinoid Tumor Arising From a Mature Cystic Teratoma of a Horseshoe Kidney. ( 28083486 )
2017
42
Lower-Extremity Vasospasm Caused by Carcinoid Syndrome. ( 29109490 )
2017
43
Carcinoid syndrome from a carcinoid tumor of the pancreas without liver metastases: A case report and literature review. ( 28454406 )
2017
44
Paraneoplastic Cushing's syndrome associated with bronchopulmonary carcinoid tumor in youth: A case report and review of the literature. ( 27347101 )
2016
45
Reply re: "Renal Carcinoid Tumor Metastatic to the Uvea, Medial Rectus Muscle, and the Contralateral Lacrimal Gland". ( 27387571 )
2016
46
Inflammatory myofibroblastic tumor of the lung in pregnancy mimicking carcinoid tumor. ( 26933315 )
2016
47
Infection with multidrug-resistant Campylobacter coli mimicking recurrence of carcinoid syndrome: a case report of a neuroendocrine tumor patient with repeated diarrhea. ( 27519265 )
2016
48
EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. ( 27214300 )
2016
49
Rectal carcinoid tumor metastasis to a skull base meningioma. ( 26825133 )
2016
50
Emerging treatment options for carcinoid syndrome. ( 27673284 )
2016
Sources

Variations for Carcinoid Syndrome

About this section
Sources

Expression for Carcinoid Syndrome

About this section
Search GEO for disease gene expression data for Carcinoid Syndrome.
Sources

Pathways for Carcinoid Syndrome

About this section

Pathways related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Neuroscience 4
11.99 CALCA ENO2 NPY SYP
2
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
11.71 HTR3A SST VEGFA
3
HIF-1 signaling pathway 37
11.13 ENO2 IGF1 VEGFA
4
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 65
10.7 IGF1 SYP VEGFA
5
Sympathetic Nerve Pathway (Neuroeffector Junction) 61
10.62 NPY PYY
Sources

GO Terms for Carcinoid Syndrome

About this section

Cellular components related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 CALCA CHGA GHRH IFNA2 IGF1 NPY
2 neuronal cell body GO:0043025 9.56 CALCA ENO2 HTR3A SST
3 terminal bouton GO:0043195 9.33 CALCA GHRH SYP
4 extracellular space GO:0005615 9.32 CALCA CHGA ENO2 GHRH IFNA2 IGF1

Biological processes related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor signaling pathway GO:0007186 9.95 CALCA GHRH NPY NTS PYY SST
2 neuropeptide signaling pathway GO:0007218 9.67 CALCA NPY PYY
3 regulation of blood pressure GO:0008217 9.54 CALCA CHGA NPY
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.5 IFNA2 IGF1 VEGFA
5 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.46 GHRH IGF1
6 positive regulation of cAMP metabolic process GO:0030816 9.43 CALCA CHGA
7 response to heat GO:0009408 9.43 CALCA IGF1 SST
8 cell-cell signaling GO:0007267 9.43 CALCA GHRH IFNA2 NPY PYY SST
9 regulation of appetite GO:0032098 9.4 NPY PYY
10 feeding behavior GO:0007631 9.33 CALCA NPY PYY
11 regulation of signaling receptor activity GO:0010469 9.28 CALCA GHRH IFNA2 IGF1 NPY NTS

Molecular functions related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 9.13 NPY NTS PYY
2 hormone activity GO:0005179 9.02 CALCA IGF1 NPY PYY SST
Sources

Sources for Carcinoid Syndrome

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....